CN111214550A - New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV - Google Patents

New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV Download PDF

Info

Publication number
CN111214550A
CN111214550A CN202010150473.5A CN202010150473A CN111214550A CN 111214550 A CN111214550 A CN 111214550A CN 202010150473 A CN202010150473 A CN 202010150473A CN 111214550 A CN111214550 A CN 111214550A
Authority
CN
China
Prior art keywords
parts
medicine
use according
new use
clearing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010150473.5A
Other languages
Chinese (zh)
Inventor
张涛涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Shenqi Pharmaceutical Co ltd
Original Assignee
Guizhou Shenqi Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Shenqi Pharmaceutical Co ltd filed Critical Guizhou Shenqi Pharmaceutical Co ltd
Priority to CN202010150473.5A priority Critical patent/CN111214550A/en
Publication of CN111214550A publication Critical patent/CN111214550A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the technical field of biological medicines. In particular to a new application of a medicine with the effects of clearing away heat and toxic materials or enhancing immunity in treating or preventing novel coronavirus pneumonia 2019-nCoV, wherein the medicine for clearing away heat and toxic materials and the medicine for enhancing immunity can be used independently or jointly. The traditional Chinese medicine composition and the conventional medicine with the health care function are adopted in the mode of new application of old medicine, and the traditional Chinese medicine composition is applied to treatment or prevention of the novel coronavirus pneumonia 2019-nCoV, has small side effect, and has good treatment effect on mild symptoms and intermediate symptoms of the novel coronavirus.

Description

New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV
Technical Field
The invention relates to the technical field of medicines, in particular to a new application of a medicine with the effects of clearing away heat and toxic materials or enhancing immunity in treating or preventing novel coronavirus pneumonia 2019-nCoV.
Background
the novel coronavirus pneumonia 2019-nCoV belongs to a novel coronavirus of beta genus, and has an envelope, particles are round or oval, are usually polymorphic and have the diameter of 60-140nm, and can be found in epithelial cells of human respiratory tracts within about 96 hours during in vitro separation culture, and are mainly spread by respiratory droplets and can also be spread by contact.
However, at present, no specific scheme is yet established clinically for the treatment or prevention of the novel coronavirus pneumonia 2019-nCoV.
Disclosure of Invention
The invention aims to provide a new application of a medicine with the effects of clearing away heat and toxic materials or enhancing immunity in treating or preventing novel coronavirus pneumonia 2019-nCoV.
In order to achieve the technical purpose, the technical scheme of the invention is as follows:
the new application of the medicine in treating or preventing the novel coronavirus pneumonia 2019-nCoV, wherein the medicine has the effects of clearing away heat and toxic materials or enhancing immunity.
In the invention, the heat-clearing and detoxifying drug and the immunity-enhancing drug can be used independently or jointly.
In the invention, the heat-clearing and detoxifying drug is a medicinal preparation prepared by adding pharmaceutically acceptable auxiliary materials into 150-250 parts of honeysuckle, 150-250 parts of centipeda minima, 50-150 parts of scutellaria baicalensis, 50-150 parts of wild chrysanthemum flower, 50-150 parts of fructus forsythiae, 5-15 parts of mint, 1-3 parts of natural borneol and 30-80 parts of liquorice in parts by weight; or the pharmaceutical preparation is prepared by adding pharmaceutically acceptable auxiliary materials into the following raw materials of 200-600 parts by weight of emilia sonchifolia, 100-500 parts by weight of solidago decurrens, 150-350 parts by weight of isatis root, 50-200 parts by weight of liquorice and 20-30 parts by weight of ginger.
More specifically, the heat-clearing and detoxifying drug is an oral and nasal spray or a cold cough syrup.
In the invention, the immunity enhancing medicine is a medicinal preparation prepared by adding pharmaceutically acceptable auxiliary materials into mannan peptide; or a medicinal preparation prepared by adding pharmaceutically acceptable auxiliary materials into amino acid and vitamin.
Specifically, the immunity enhancing medicine is a mannan peptide tablet or a compound amino acid (8) vitamin capsule (11).
Wherein, the oral nose spray or the syrup for treating cold and cough is taken according to the conventional dosage when being used independently, and the dosage is reduced by half when the oral nose spray or the syrup for treating cold and cough is used jointly.
The mannan peptide tablet or the compound amino acid (8) vitamin capsule (11) is taken according to the conventional dosage when being used independently, and the dosage is reduced by half when the mannan peptide tablet or the compound amino acid (8) vitamin capsule are used jointly.
When the heat-clearing and detoxifying drug and the immunopotentiating drug are used together, the heat-clearing and detoxifying drug is taken according to the conventional dose, and the dose of the immunopotentiating drug is reduced by half.
Compared with the prior art, the invention has the following beneficial effects: the traditional Chinese medicine composition and the conventional medicine with the health care function are adopted in the mode of new application of old medicine, and the traditional Chinese medicine composition is applied to treatment or prevention of the novel coronavirus pneumonia 2019-nCoV, has small side effect, and has good treatment effect on mild symptoms and intermediate symptoms of the novel coronavirus.
Detailed Description
The present invention is further illustrated by the following specific examples, which are not intended to limit the scope of the invention as claimed herein, in regard to the particular data and operations involved.
Example 1
1. Experimental drug and experimental subject
1.1 test drugs of Konjianqing spray, Ganmaoyankeling syrup, mannan peptide tablet and compound amino acid (8) vitamin capsule (11) are provided by Guizhou Shenqi pharmaceutical industry Co.
1.2 general data
200 patients diagnosed with the novel coronavirus pneumonia were selected. The specific distribution is shown in table 1 below:
table 1: basic cases of outpatient grouping
Figure RE-GDA0002455479680000021
1.3 diagnostic criteria
(1) The body temperature is normal for 3 days;
(2) the respiratory symptoms are obviously improved;
(3) chest imaging showed significant absorption of inflammation;
(4) nucleic acid detection in respiratory hospital is negative for two times.
2. Method of treatment
2.1 treatment group
Specific treatment conditions are shown in table 2 below:
Figure RE-GDA0002455479680000031
as can be seen from the above table, there was no significant difference in the distribution of the basic indices for each treatment group.
The above treatment groups used therapeutic amounts of the drugs according to the instructions, 3 times a day.
3. Results
3.1 Observation index
And observing body temperature, appetite, hypodynamia, CT, respiration, nucleic acid detection results and the like, and recording by adopting an integration method.
3.2 evaluation criteria for comprehensive therapeutic effects
Complete response (significant):
(1) the body temperature is normal for 3 days;
(2) the respiratory symptoms are obviously improved;
(3) chest imaging showed significant absorption of inflammation;
(4) nucleic acid detection of respiratory disease hospital is negative for two times;
partial response (effective):
(1) the body temperature is normal;
(2) respiratory symptoms are improved;
(3) chest imaging showed absorption of inflammation;
(4) positive nucleic acid detection in respiratory hospital;
no response (null): those which do not meet the above criteria.
3.4 Total efficacy analysis
No adverse reaction is seen during and after treatment.
(1) Signs of symptoms: the symptoms of each group of the treatment groups are improved to different degrees, and P is less than 0.01; the pharmaceutical composition of the invention can obviously improve the symptoms of patients. (P < 0.05, see Table 3).
Table 3: integral change of body temperature, other symptoms and signs before and after treatment (x + -s, n ═ 200)
Figure RE-GDA0002455479680000041
P < 0.01, P < 0.05 before and after treatment for each group.
(2) Comprehensive curative effect:
table 4: combination therapy of conditions
Figure RE-GDA0002455479680000042
Figure RE-GDA0002455479680000051
From the above results, it can be seen that the therapeutic agent of the present invention has an obvious therapeutic effect on the novel coronavirus pneumonia.
4. Enumerating several cases of specific clinical cases
Case 1: liu Jie, Guizhou Guiyang people, male, 57 years old, 2020, 1 month, 24 days old and short by 37.4 ℃, three times a day, the belly pulled, one side of the lung infected seriously, the other side slight, and the blood test is all normal. In a fever day of 1 month and 25 days, at the home, the oral-nasal spray and the mannan peptide tablet are taken at 28 ℃ and 26 months after the day of 1 month according to the instructions, on the day of medication, the body temperature rises to 38.7 ℃, the temperature is recovered to 36.6 ℃ in the morning of No. 31, the temperature is more than 4 pm, the body temperature is recovered to 37.2 ℃, but the temperature is recovered to be normal to 36.6 ℃ in the evening, the appetite is obviously increased, the lung CT is rechecked, and the inflammation is obviously absorbed.
Case 2: the oral and nasal spray and the mannan peptide tablet are taken from 1 month and 31 days according to the instructions for 2 months and 3 days, the temperature of the bedridden precursor is 37.8 ℃, no antipyretic is taken, the fever is abated in the morning for 2 months and 4 days, the administration is continued for one week, the body temperature is maintained at about 36 ℃ all the time, the appetite is recovered, and the body is recovered to be healthy.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made without departing from the spirit and scope of the invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.

Claims (9)

1. The new application of the medicine in treating or preventing the novel coronavirus pneumonia 2019-nCoV is characterized in that: the medicine has the functions of clearing away heat and toxic material or enhancing immunity.
2. The new use according to claim 1, characterized in that: the heat-clearing and detoxifying drug and the immunity-enhancing drug can be used independently or in combination.
3. The new use according to claim 2, characterized in that: the heat-clearing and detoxifying drug is a medicinal preparation prepared by adding pharmaceutically acceptable auxiliary materials into 150-250 parts of honeysuckle, 150-250 parts of centipeda minima, 50-150 parts of southwest scutellaria baicalensis, 50-150 parts of wild chrysanthemum, 50-150 parts of fructus forsythiae, 5-15 parts of mint, 1-3 parts of natural borneol and 30-80 parts of liquorice by weight; or the pharmaceutical preparation is prepared by adding pharmaceutically acceptable auxiliary materials into the following raw materials of 200-600 parts by weight of emilia sonchifolia, 100-500 parts by weight of solidago decurrens, 150-350 parts by weight of isatis root, 50-200 parts by weight of liquorice and 20-30 parts by weight of ginger.
4. The new use according to claim 3, characterized in that: the heat-clearing and detoxifying drug is an oral and nasal spray or a syrup for treating cold and cough.
5. The new use according to claim 2, characterized in that: the immunity enhancing medicine is a medicinal preparation prepared by adding pharmaceutically acceptable auxiliary materials into mannan peptide; or a medicinal preparation prepared by adding pharmaceutically acceptable auxiliary materials into amino acid and vitamin.
6. The new use according to claim 5, characterized in that: the immunity enhancing medicine is a mannan peptide tablet or a compound amino acid (8) vitamin capsule (11).
7. The new use according to claim 4, characterized in that: the oral nasal spray or the syrup for treating cold and cough is taken according to the conventional dosage when being used independently, and the dosage is reduced by half when the oral nasal spray or the syrup for treating cold and cough is used jointly.
8. The new use according to claim 6, characterized in that: the mannan peptide tablet or the compound amino acid (8) and vitamin capsule (11) is taken according to the conventional dosage when being used independently, and the dosage is reduced by half when the mannan peptide tablet and the compound amino acid (8) and the vitamin capsule are used jointly.
9. The new use according to claim 2, characterized in that: when the heat-clearing and detoxifying drug and the immunity-enhancing drug are used together, the heat-clearing and detoxifying drug is taken according to the conventional dosage, and the dosage of the immunity-enhancing drug is reduced by half.
CN202010150473.5A 2020-03-06 2020-03-06 New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV Pending CN111214550A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010150473.5A CN111214550A (en) 2020-03-06 2020-03-06 New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010150473.5A CN111214550A (en) 2020-03-06 2020-03-06 New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV

Publications (1)

Publication Number Publication Date
CN111214550A true CN111214550A (en) 2020-06-02

Family

ID=70812147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010150473.5A Pending CN111214550A (en) 2020-03-06 2020-03-06 New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV

Country Status (1)

Country Link
CN (1) CN111214550A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643621A (en) * 2020-06-09 2020-09-11 万天石 Antiviral traditional Chinese medicine composition, preparation method and application thereof
CN112057488A (en) * 2020-11-11 2020-12-11 中国医学科学院肿瘤医院 COVID-19 prevention and treatment medicine for inhibiting virus receptor ACE2 and application thereof
CN116159112A (en) * 2022-11-20 2023-05-26 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Pharmaceutical composition for preventing novel coronavirus infection, and preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
微博: "柳叶刀助攻我的抗新冠肺炎方案-已成功救助大量患者", 《HTTPS://WEIBO.COM/TTARTICLE/P/SHOW?ID=2309634468404508557527》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643621A (en) * 2020-06-09 2020-09-11 万天石 Antiviral traditional Chinese medicine composition, preparation method and application thereof
CN112057488A (en) * 2020-11-11 2020-12-11 中国医学科学院肿瘤医院 COVID-19 prevention and treatment medicine for inhibiting virus receptor ACE2 and application thereof
CN116159112A (en) * 2022-11-20 2023-05-26 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Pharmaceutical composition for preventing novel coronavirus infection, and preparation method and application thereof

Similar Documents

Publication Publication Date Title
EP2450047B1 (en) Pharmaceutical composition containing ephedrae for treating bronchitis and preparation method therefor
WO2016062270A1 (en) Use of respiratory disease medication in preparation of anti-cancer pharmaceutical composition
CN111214550A (en) New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV
CA3166282A1 (en) Use of pharmaceutical composition for preventing and treating novel coronavirus pneumonia
CN102319294B (en) Double-vanilla preparation and preparation method thereof
CN101244193A (en) Traditional Chinese medicine for treating respiratory disease and method for preparing the same
CN111281914A (en) Traditional Chinese medicine composition for treating pneumonia
CN1129450C (en) Medicine for clearing away heat and toxic material and its prepn
CN100579557C (en) Cough-stopping granule with honeysuckle flower and bulbus fritilariae
CN102139051B (en) Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia
CN111214637A (en) Traditional Chinese medicine composition and preparation method and medicinal application thereof
CN113476562B (en) Composition and preparation method and application thereof
CN102552734B (en) Gargle for treating dental ulcer
CN1025478C (en) Nose liniment and preparing process
CN100563677C (en) A kind of moistening and cleaning throat Chinese medicine preparation
CN109663012A (en) Dispelling wind and heat, removing toxic substances relieving sore-throat Chinese medicine composition and the preparation method and application thereof
Li et al. Study on the Effect of Self-Made Lifei Dingchuan Decoction Combined with Western Medicine on Cough Variant Asthma
CN109865123A (en) A kind of pharmaceutical composition and its preparation method and application for treating recurrent oral ulceration
CN115282243B (en) Traditional Chinese medicine composition for treating pediatric acute bronchitis and preparation method thereof
WO2003090749A1 (en) Use of berberine with high solubility in preparation of medicament
CN101618157B (en) Medicine composition for treating autumn-dryness cold and preparation method thereof
CN108578549B (en) Medicine for treating acne and application thereof
CN117653637A (en) New application of entecavir
CN1481892A (en) Reptile phrynosoma tablet for curing pulmonary disease
CN115105566A (en) Traditional Chinese medicine composition for treating laryngeal cough and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200602